TG Therapeutics Inc Share Price Today: Live Updates & Key Insights

TG Therapeutics Inc share price today is $30.05, up -0.96%. The stock opened at $30.4 against the previous close of $30.36, with an intraday high of $30.45 and low of $29.47.

TG Therapeutics Inc Share Price Chart

TG Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

TG Therapeutics Inc Share Price Performance

$30.05 -0.0096(-0.96%) TGTX at 23 Mar 2026 03:29 PM Biotechnology
Lowest Today 29.47
Highest Today 30.45
Today’s Open 30.4
Prev. Close 30.36
52 Week High 46.48
52 Week Low 25.28
Day’s Range: Low 29.47 High 30.45
52-Week Range: Low 25.28 High 46.48
1 day return -
1 Week return +4.8
1 month return -1.47
3 month return -3.33
6 month return -13.9
1 year return -29.29
3 year return +111.37
5 year return -40.24
10 year return -

TG Therapeutics Inc Institutional Holdings

BlackRock Inc 13.34

Vanguard Group Inc 9.92

iShares Core S&P Small-Cap ETF 5.16

State Street Corp 5.07

Vanguard Total Stock Mkt Idx Inv 3.00

ClearBridge Advisors, LLC 2.91

Soleus Capital Management, L.P. 2.41

iShares Russell 2000 ETF 2.21

Vanguard Small Cap Index 2.14

Geode Capital Management, LLC 2.13

State Street® SPDR® S&P® Biotech ETF 1.99

Congress Asset Management Company, LLP 1.20

Vanguard Small Cap Growth Index Inv 1.19

Hood River Capital Management LLC 0.99

The Goldman Sachs Group Inc 0.95

Northern Trust Corp 0.94

Vanguard Institutional Extnd Mkt Idx Tr 0.92

Pictet Asset Manangement SA 0.91

Fidelity Small Cap Index 0.89

Charles Schwab Investment Management Inc 0.82

Vanguard Explorer Inv 0.82

State Street SPDR Port S&P 600 Sm CpETF 0.79

Morgan Stanley - Brokerage Accounts 0.78

iShares Russell 2000 Growth ETF 0.76

iShares S&P Small-Cap 600 Growth ETF 0.73

Congress Small Cap Growth Institutional 0.73

Amvescap Plc. 0.69

Two Sigma Investments LLC 0.66

Citadel Advisors Llc 0.63

Invesco S&P SmallCap Momentum ETF 0.61

Jane Street Group LLC 0.61

ClearBridge Small Cap Growth 0.61

ClearBridge Small Cap Growth A 0.61

T. Rowe Price Associates, Inc. 0.60

Man Group PLC 0.60

Nuveen, LLC 0.60

Pictet-Biotech P USD 0.59

Hood River Small-Cap Growth Instl 0.58

Vanguard Tax-Managed Small Cap Adm 0.55

State St Russell Sm/Mid Cp® Indx SL Cl I 0.53

TG Therapeutics Inc Market Status

Strong Buy: 5

Buy: 1

Hold: 0

Sell: 1

Strong Sell: 0

TG Therapeutics Inc Fundamentals

Market Cap 4801.83 M

PB Ratio 7.41

PE Ratio 10.8556

Enterprise Value 4913.57 M

Total Assets 1063.25 M

Volume 5061399

TG Therapeutics Inc Company Financials

Annual Revenue FY25:null 0.0M, FY24:233662000 233.7M, FY23:233662000 233.7M, FY22:2785000 2.8M, FY21:6689000 6.7M

Annual Profit FY25:null 0.0M, FY24:219531000 219.5M, FY23:219108000 219.1M, FY22:2520000 2.5M, FY21:5899000 5.9M

Annual Net worth FY25:447179000 447.2M, FY24:12672000 12.7M, FY23:12672000 12.7M, FY22:-203831000 -203.8M, FY21:-355552000 -355.6M

Quarterly Revenue Q3/2025:161709000 161.7M, Q2/2025:141148000 141.1M, Q1/2025:120856000 120.9M, Q3/2024:83879000 83.9M, Q2/2024:73466000 73.5M

Quarterly Profit Q3/2025:133554000 133.6M, Q2/2025:122210000 122.2M, Q1/2025:105315000 105.3M, Q3/2024:74538000 74.5M, Q2/2024:65090001 65.1M

Quarterly Net worth Q3/2025:390895000 390.9M, Q2/2025:28187000 28.2M, Q1/2025:5060000 5.1M, Q3/2024:3880000 3.9M, Q2/2024:6879000 6.9M

About TG Therapeutics Inc & investment objective

Company Information TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Organisation Biotechnology

Employees 399

Industry Biotechnology

CEO Mr. Michael S. Weiss Esq., J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

TG Therapeutics Inc FAQs

What is the share price of TG Therapeutics Inc today?

The current share price of TG Therapeutics Inc is $30.05.

Can I buy TG Therapeutics Inc shares in India?

Yes, Indian investors can buy TG Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy TG Therapeutics Inc shares in India?

You can easily invest in TG Therapeutics Inc shares from India by:

Can I buy fractional shares of TG Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of TG Therapeutics Inc?

TG Therapeutics Inc has a market cap of $4801.83 M.

In which sector does TG Therapeutics Inc belong?

TG Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in TG Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of TG Therapeutics Inc?

The PE ratio of TG Therapeutics Inc is 10.86 and the PB ratio is 7.41.